These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 27224423)
1. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals? Stone J; Martin NK; Hickman M; Hellard M; Scott N; McBryde E; Drummer H; Vickerman P PLoS One; 2016; 11(5):e0156213. PubMed ID: 27224423 [TBL] [Abstract][Full Text] [Related]
2. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. Scott N; McBryde E; Vickerman P; Martin NK; Stone J; Drummer H; Hellard M BMC Med; 2015 Aug; 13():198. PubMed ID: 26289050 [TBL] [Abstract][Full Text] [Related]
3. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago. Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092 [TBL] [Abstract][Full Text] [Related]
4. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808 [TBL] [Abstract][Full Text] [Related]
5. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting? Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585 [TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Bruggmann P; Blach S; Deltenre P; Fehr J; Kouyos R; Lavanchy D; Müllhaupt B; Rauch A; Razavi H; Schmid P; Semela D; Stoeckle M; Negro F Swiss Med Wkly; 2017; 147():w14543. PubMed ID: 29120012 [TBL] [Abstract][Full Text] [Related]
7. The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. Scott N; Wilson DP; Thompson AJ; Barnes E; El-Sayed M; Benzaken AS; Drummer HE; Hellard ME BMC Med; 2019 Sep; 17(1):175. PubMed ID: 31530275 [TBL] [Abstract][Full Text] [Related]
8. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). Hickman M; Dillon JF; Elliott L; De Angelis D; Vickerman P; Foster G; Donnan P; Eriksen A; Flowers P; Goldberg D; Hollingworth W; Ijaz S; Liddell D; Mandal S; Martin N; Beer LJZ; Drysdale K; Fraser H; Glass R; Graham L; Gunson RN; Hamilton E; Harris H; Harris M; Harris R; Heinsbroek E; Hope V; Horwood J; Inglis SK; Innes H; Lane A; Meadows J; McAuley A; Metcalfe C; Migchelsen S; Murray A; Myring G; Palmateer NE; Presanis A; Radley A; Ramsay M; Samartsidis P; Simmons R; Sinka K; Vojt G; Ward Z; Whiteley D; Yeung A; Hutchinson SJ BMJ Open; 2019 Sep; 9(9):e029538. PubMed ID: 31551376 [TBL] [Abstract][Full Text] [Related]
9. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic. Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093 [TBL] [Abstract][Full Text] [Related]
10. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. Martin NK; Foster GR; Vilar J; Ryder S; Cramp ME; Gordon F; Dillon JF; Craine N; Busse H; Clements A; Hutchinson SJ; Ustianowski A; Ramsay M; Goldberg DJ; Irving W; Hope V; De Angelis D; Lyons M; Vickerman P; Hickman M J Viral Hepat; 2015 Apr; 22(4):399-408. PubMed ID: 25288193 [TBL] [Abstract][Full Text] [Related]
11. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600 [TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Hickman M; De Angelis D; Vickerman P; Hutchinson S; Martin NK Curr Opin Infect Dis; 2015 Dec; 28(6):576-82. PubMed ID: 26524330 [TBL] [Abstract][Full Text] [Related]
13. Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections. Bennett H; McEwan P; Sugrue D; Kalsekar A; Yuan Y PLoS One; 2015; 10(5):e0125846. PubMed ID: 25938458 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Martin NK; Vickerman P; Grebely J; Hellard M; Hutchinson SJ; Lima VD; Foster GR; Dillon JF; Goldberg DJ; Dore GJ; Hickman M Hepatology; 2013 Nov; 58(5):1598-609. PubMed ID: 23553643 [TBL] [Abstract][Full Text] [Related]
15. Potential impact of curative and preventive interventions toward hepatitis C elimination in people who inject drugs-A network modeling study. Zhu L; Thompson WW; Hagan L; Randall LM; Rudolph AE; Young AM; Havens JR; Salomon JA; Linas BP Int J Drug Policy; 2024 Aug; 130():104539. PubMed ID: 39033645 [TBL] [Abstract][Full Text] [Related]
16. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study. Smit C; Boyd A; Rijnders BJA; van de Laar TJW; Leyten EM; Bierman WF; Brinkman K; Claassen MAA; den Hollander J; Boerekamps A; Newsum AM; Schinkel J; Prins M; Arends JE; Op de Coul ELM; van der Valk M; Reiss P; Lancet HIV; 2021 Feb; 8(2):e96-e105. PubMed ID: 33357835 [TBL] [Abstract][Full Text] [Related]
17. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789 [TBL] [Abstract][Full Text] [Related]
18. Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago. Echevarria D; Gutfraind A; Boodram B; Major M; Del Valle S; Cotler SJ; Dahari H PLoS One; 2015; 10(8):e0135901. PubMed ID: 26295805 [TBL] [Abstract][Full Text] [Related]
19. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Hellard ME; Jenkinson R; Higgs P; Stoové MA; Sacks-Davis R; Gold J; Hickman M; Vickerman P; Martin NK Med J Aust; 2012 Jun; 196(10):638-41. PubMed ID: 22676879 [TBL] [Abstract][Full Text] [Related]
20. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]